Limbix
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Limbix was a digital therapeutics company founded in 2016, developing evidence-based treatments for teens and young adults with symptoms of depression. It started with the Limbix VR Kit for exposure therapy and later pivoted to prescription digital therapeutics: SparkRx, a self-guided cognitive behavioral therapy (CBT) program for those aged 13+, teaching mood tracking, behavioral activation, problem solving and mindfulness, supported by trial data showing clinically meaningful reductions in depression symptoms. It raised about $30 million through its Series A, including a $15 million round in late 2021.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Founded in 2016 to build research-based digital therapeutics for adolescent mental health, starting with VR programs.
- Series A extension
Raised $15 million in late 2021 at the peak of the digital health fundraising boom, bringing total funding to about $30 million; focused on prescription DTx with SparkRx completing a pivotal clinical trial.
- Acquired by Big Health
On July 14, 2023, Big Health acquired Limbix for an undisclosed amount, adding SparkRx for adolescent depression (plus an adolescent anxiety product in development) to its portfolio of digital therapeutics alongside Sleepio and Daylight.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.